Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526842 | 0.88 | CHRNA7 (0.54) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL4453290 | 0.83 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL1786140 | 0.83 | MEN1 (0.69) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL31000129 | 0.81 | CHRNA7 (0.63) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL9592504 | 0.80 | POLB (0.49) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL9518832 | 0.80 | POLB (0.49) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL9517909 | 0.80 | POLB (0.49) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL9248196 | 0.80 | MEN1 (0.65) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL1926317 | 0.80 | MEN1 (0.65) | CHRNA7MEN1KMT2AGAAHTR3E | |
| SCHEMBL21286806 | 0.79 | MEN1 (0.59) | CHRNA7MEN1KMT2AGAAHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600728-B2 | Interleukin-17 inhibitors | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| EP-4642785-A1 | IL-17A MODULATORS | Usynova Pharmaceuticals Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024138286-A1 | IL-17A MODULATORS | USYNOVA PHARMACEUTICALS, LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024139171-A1 | IL-17A MODULATORS | USYNOVA PHARMACEUTICALS, LTD. (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2023-12-07 | — | — | US | disclosed |
| EP-4237417-A1 | INTERLEUKIN-17 INHIBITORS | Novartis AG (CH) | 2023-09-06 | — | — | EP | disclosed |
| CN-116323596-A | Interleukin-17 inhibitors | 诺华股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022091056-A1 | INTERLEUKIN-17 INHIBITORS | NOVARTIS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| WO-2011060000-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059887-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| US-6313365-B1 | Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| US-6175047-B1 | A CATALYST MIXTURE INCLUDING A RUTHENIUM COMPOUND, A DIHALOGENO COMPOUND, A TERMINAL ALKYNE; AS A CATALYST FOR A CARBON-CARBON BOND FORMATION REACTION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0927577-A1 | Ruthenium metathesis catalyst and method for producing olefin reaction product by metathesis reaction using the same | Takasago International Corporation (JP) | 1999-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391782-A1 | INTERLEUKIN-17 INHIBITORS | IL17A, IL2, IL18 | CHRNA7 2551/4885MEN1 3778/4885KMT2A 3012/4885 |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | CHRNA7 4487/4885MEN1 2161/4885KMT2A 1961/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CHRNA7 4585/4885MEN1 4867/4885KMT2A 4516/4885 |
| US-12600728-B2 | Interleukin-17 inhibitors | IL17A, IL2, IL1B | CHRNA7 1638/4885MEN1 3383/4885KMT2A 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.